Pharmacyclics, Inc. (NASDAQ:PCYC)

CAPS Rating: 2 out of 5

A pharmaceutical company focused on the development of products that improve existing therapeutic approaches to cancer and other diseases.

Recs

0
Player Avatar TMFBiologyFool (98.65) Submitted: 7/2/2012 1:38:57 PM : Underperform Start Price: $57.52 PCYC Score: -19.00

Ibrutinib has potential, but risk reward is too unfavorable after the run up.

Featured Broker Partners


Advertisement